About ReBio
ReBio is a company based in Cranleigh (United Kingdom) founded in 2014. ReBio operates in a competitive market with competitors including Fractyl, GI Dynamics, MetaModix, Allevetix and EndObetes, among others.
- Headquarter Cranleigh, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ReBio
Unlock access to complete
Leadership Team
2 people
Product Management Team
2 people
CTO Team
1 people
Administrative Team
1 people
Unlock access to complete
Funding Insights of ReBio
Detailed funding history for ReBio
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReBio
Investment portfolio details for ReBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ReBio
Detailed financials for ReBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rebio Comparisons
Peer comparison for ReBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReBio
ReBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fractyl, GI Dynamics, MetaModix, Allevetix and EndObetes, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Endoscopic barriers for diabetes and metabolic disease treatment are developed.
|
|
| Locked | Locked | Locked |
Endoscopically introduced bile diversion device
|
|
| Locked | Locked | Locked |
Developer of device for controlling hormonal balance
|
|
| Locked | Locked | Locked |
Surgical access tool for obesity and diabetes treatment is developed.
|
|
| Locked | Locked | Locked |
Non-invasive medical devices for diabetes treatment are developed.
|
Detailed competitors of ReBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rebio
Complete news archive for ReBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReBio
ReBio was founded in 2014.
ReBio is headquartered in Cranleigh, United Kingdom.
Harri Jukarainen is the current CEO of ReBio.
ReBio was founded in 2014 in Cranleigh, United Kingdom. Development efforts are directed toward GLP-1 receptor agonists for Type 2 Diabetes treatment within the biotechnology sector. A proprietary bio-resorbable and biocompatible polymer synthesis method, known as SISU, has been created to enable controlled drug release in therapeutic formulations. Operations remain focused on advancing diabetes management solutions from the UK base.
ReBio's top competitors include Fractyl, GI Dynamics and EndObetes.